X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (45) 45
oncology (44) 44
index medicus (41) 41
male (23) 23
cancer (20) 20
chemotherapy (20) 20
head and neck cancer (20) 20
head and neck neoplasms - drug therapy (19) 19
antineoplastic combined chemotherapy protocols - therapeutic use (17) 17
female (17) 17
middle aged (17) 17
carcinoma, squamous cell - drug therapy (16) 16
aged (15) 15
head and neck neoplasms - pathology (13) 13
treatment outcome (13) 13
adult (12) 12
cisplatin (12) 12
squamous cell carcinoma (12) 12
cetuximab (11) 11
human medicine (11) 11
squamous-cell carcinoma (11) 11
care and treatment (10) 10
locally advanced head (10) 10
phase-ii trial (10) 10
radiotherapy (10) 10
cisplatin - administration & dosage (9) 9
metastatic (9) 9
neoplasm recurrence, local - drug therapy (9) 9
disease-free survival (8) 8
head and neck neoplasms - radiotherapy (8) 8
induction chemotherapy (8) 8
medicine & public health (8) 8
radiation therapy (8) 8
chemoradiotherapy (7) 7
fluorouracil - administration & dosage (7) 7
lung-cancer (7) 7
radiation-therapy (7) 7
recurrent (7) 7
trial (7) 7
antibodies, monoclonal, humanized - therapeutic use (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
cancer patients (6) 6
carcinoma, squamous cell - pathology (6) 6
chemoradiation (6) 6
fluorouracil (6) 6
research (6) 6
antibodies, monoclonal - administration & dosage (5) 5
antibodies, monoclonal - therapeutic use (5) 5
antineoplastic agents - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
carcinoma, squamous cell - radiotherapy (5) 5
cisplatin plus fluorouracil (5) 5
cooperative-oncology-group (5) 5
diagnosis (5) 5
docetaxel (5) 5
drug administration schedule (5) 5
dysphagia (5) 5
growth-factor-receptor (5) 5
hematology, oncology and palliative medicine (5) 5
melanoma (5) 5
melanoma - drug therapy (5) 5
metastasis (5) 5
metastatic melanoma (5) 5
neoplasm metastasis (5) 5
neoplasm staging (5) 5
nivolumab (5) 5
pharmacology & pharmacy (5) 5
phase-ii (5) 5
platinum-based chemotherapy (5) 5
quality of life (5) 5
squamous cell carcinoma of head and neck (5) 5
survival rate (5) 5
taxoids - administration & dosage (5) 5
tumors (5) 5
adverse events (4) 4
analysis (4) 4
animals (4) 4
antibodies, monoclonal - adverse effects (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
bevacizumab (4) 4
brain neoplasms - drug therapy (4) 4
cancer therapies (4) 4
drug therapy (4) 4
glioblastoma - drug therapy (4) 4
head & neck cancer (4) 4
head and neck neoplasms - therapy (4) 4
immunotherapy (4) 4
ipilimumab (4) 4
maximum tolerated dose (4) 4
melanoma - pathology (4) 4
neck-cancer (4) 4
neoplasm recurrence, local - pathology (4) 4
neoplasms (4) 4
patient outcomes (4) 4
pharmacokinetics (4) 4
quality-of-life (4) 4
rehabilitation (4) 4
resistance (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 03/2019, Volume 20, Issue 5, pp. 495 - 500
Journal Article
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 05/2018, Volume 18, Issue 5, pp. 409 - 420
Introduction: The prognosis of recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (HNSCC) after failure of first line chemotherapy is... 
pembrolizumab | head and neck cancer | metastatic | nivolumab | HNSCC | second line | adverse events | Anti-PD1 | recurrent | ADVANCED CANCER | IMMUNE CHECKPOINT INHIBITORS | ADRENOCORTICOTROPIC HORMONE DEFICIENCY | PSORIASIS-VULGARIS | DIABETES-MELLITUS | HEMOLYTIC-ANEMIA | METASTATIC MELANOMA | ONCOLOGY | ACUTE INTERSTITIAL NEPHRITIS | ORGANIZING PNEUMONIA | CLINICAL ACTIVITY
Journal Article
Journal Article
EXPERT REVIEW OF ANTICANCER THERAPY, ISSN 1473-7140, 01/2012, Volume 12, Issue 1, pp. 9 - 18
Bevacizumab is a humanized IgG1 monoclonal antibody that selectively binds with high affinity to human VEGF and neutralizes VEGF's biologic activity. Malignant... 
glioblastoma multiforme | PLUS IRINOTECAN | TUMOR PROGRESSION | METRONOMIC CHEMOTHERAPY | ADJUVANT TEMOZOLOMIDE | RADIATION-THERAPY | newly diagnosed | PHASE-II TRIAL | RECURRENT MALIGNANT GLIOMA | ONCOLOGY | SINGLE-AGENT BEVACIZUMAB | bevacizumab | OPTIC NEUROPATHY | RADIOTHERAPY | recurrent
Journal Article
Biologics: Targets and Therapy, ISSN 1177-5475, 04/2013, Volume 7, Issue 1, pp. 77 - 90
Overviews the role of Cetuximab, in combination with radiotherapy (RT), platinum-based chemoradiation (CRT), or platinum-based chemotherapy, as treatment for... 
SCCHN | Cetuximab | Recurrent metastatic | Chemoradiation | Locoregionally advanced | Head | Squamous cell carcinoma | Treatment | Neck | Cancer | Head & neck cancer | cetuximab | Review | locoregionally advanced | chemoradiation | recurrent metastatic
Journal Article
Acta Clinica Belgica, ISSN 1784-3286, 01/2016, Volume 71, Issue S1, p. 13
  Early phase I trials with ptx were complicated by a high incidence of HSR. For ptx administered every 3 weeks, the FDA recommends the use of premedication... 
Side effects
Journal Article
Acta Clinica Belgica, ISSN 1784-3286, 01/2016, Volume 71, Issue S1, p. 30
  Primary malignant melanoma of the esophagus (PMME) is an extremely rare diagnosis. There are only around 350 case reports in literature, half of which are... 
Medical prognosis | Melanoma | Dysphagia | Mutation | Family medical history | Skin cancer | Esophagus
Journal Article
Acta Clinica Belgica, ISSN 1784-3286, 01/2016, Volume 71, Issue S1, p. 16
  The future challenge to oncologists will be the growing group of ECP. The decision to start CT in this group of patients should not be made based on calendar... 
Studies | Chemotherapy | Geriatrics
Journal Article
by Cohen, Ezra E W and Cohen, Ezra and Soulières, Denis and Le Tourneau, Christophe and Dinis, Jose and Dinis, José and Licitra, Lisa and Ahn, Myung-Ju and Soria, Ainara and Machiels, Jean-Pascal and Mach, Nicolas and Mehra, Ranee and Burtness, Barbara Ann and Burtness, Barbara and Zhang, Pingye and Cheng, Jonathan and Swaby, Ramona F and Harrington, Kevin and Harrington, Kevin J and Acosta-Rivera, Mirelis and Adkins, Douglas R and Aghmesheh, Morteza and Airoldi, Mario and Aleknavicius, Eduardas and Al-Farhat, Yousuf and Algazi, Alain P and Almokadem, Salah and Alyasova, Anna and Bauman, Jessica R and Benasso, Marco and Berrocal, Alfonso and Bray, Victoria and Caponigro, Francesco and Castro, Ana and Cescon, Terrence P and Chan, Kelvin and Chaudhry, Arvind and Chauffert, Bruno and Csoszi, Tibor and De Boer, J.P and Delord, Jean-Pierre and Dietz, Andreas and Dupuis, Charlotte and Digue, Laurence and Erfan, Jozsef and Escobar Alvarez, Yolanda and Evans, Mererid and Fidler, Mary Jo and Forster, Martin David and Friesland, Signe and Ganti, Apar K and Geoffrois, Lionnel and Grant, Cliona and Gruenwald, Viktor and Hoffmann, Thomas and Horvai, Geza and Inciura, Arturas and Jang, Raymond and Jankowska, Petra and Jimeno, Antonio and Joseph, Mano and Juarez Ramiro, Alejandro and Karaszewska, Boguslawa and Kawecki, Andrzej and Keilholz, Ulrich and Keller, Ulrich and Kim, Sung-Bae and Kocsis, Judit and Kotecki, Nuria and Kozloff, Mark F and Lambea, Julio and Landherr, Laszlo and Lantsukhay, Yuri and Lazarev, Sergey Alexandrovich and Lee, Lip Way and Lifirenko, Igor Dmitrievich and Martincic, Danko and Matorin, Oleg Vladmirovhich and McGrath, Margaret and Misiukiewicz, Krzysztof and Morris, John C and Mufazalov, Fagim Fanisovich and Niu, Jiaxin and Pamoorthy Srinivasan, Devraj and Perez Segura, Pedro and Rauch, Daniel and Ribeiro, Maria Leonor and Rodriguez, Cristina and Rolland, Frederic and Russo, Antonio and Ruzsa, Agnes and Sanches, Frederico and Shin, Sang-Won and Shtiveland, Mikhail and Soulieres, Denis and Specenier, Pol and Szekanecz, Eva and Szota, Judit and van Herpen, Carla M.L and Velez-Cortes, Hector A and ... and Keynote-040 Investigators and KEYNOTE-040 investigators
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 156 - 167
There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour... 
CRITERIA | TRIAL | MEDICINE, GENERAL & INTERNAL | NIVOLUMAB | CANCER | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Docetaxel - adverse effects | Humans | Middle Aged | Squamous Cell Carcinoma of Head and Neck - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Cetuximab - therapeutic use | Cetuximab - adverse effects | Docetaxel - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Squamous Cell Carcinoma of Head and Neck - drug therapy | Female | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Disease Progression | Head and Neck Neoplasms - pathology | Methotrexate - adverse effects | Squamous Cell Carcinoma of Head and Neck - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cetuximab - administration & dosage | Methotrexate - administration & dosage | Aged | Methotrexate | Squamous cell carcinoma | Metastasis | Therapy | Toxicity | Perforation | Clinical trials | Oncology | Cancer therapies | Metastases | Skin cancer | Anticancer properties | Pembrolizumab | Randomization | Motivation | Platinum | Neck | Safety | Medical treatment | Fatigue | Hypothyroidism | Survival | Patients | Chemotherapy | Interactive systems | Large intestine | Head and neck cancer | Ligands | Tumors
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 04/2011, Volume 11, Issue 4, pp. 511 - 524
The majority of the head and neck cancers are squamous cell carcinomas, which commonly overexpress the EGF receptor (EGFR). Cetuximab is a chimeric monoclonal... 
locoregionally advanced disease | SCCHN | cetuximab | head and neck cancer | recurrent and metastatic disease | PLUS CETUXIMAB | RANDOMIZED-TRIAL | RADIATION-THERAPY | SEVERE CUTANEOUS REACTION | ONCOLOGY | RECEPTOR ANTIBODY CETUXIMAB | PLATINUM-BASED CHEMOTHERAPY | LOCALLY ADVANCED HEAD | PHASE-II MULTICENTER | QUALITY-OF-LIFE | CONCURRENT CETUXIMAB | Humans | Antibodies, Monoclonal - therapeutic use | Head and Neck Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Squamous Cell Carcinoma of Head and Neck | Fluorouracil - administration & dosage | Neoplasms, Squamous Cell - drug therapy | Neoplasms, Squamous Cell - radiotherapy | Chemotherapy, Adjuvant | Cetuximab | Carcinoma - drug therapy | ErbB Receptors - antagonists & inhibitors | Antibodies, Monoclonal - pharmacology | Head and Neck Neoplasms - drug therapy | Antibodies, Monoclonal - pharmacokinetics | Clinical Trials as Topic | Carcinoma - radiotherapy | Carcinoma, Squamous Cell | Head and Neck Neoplasms - radiotherapy | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma - metabolism | Neoplasms, Squamous Cell - metabolism | Head and neck cancer | Squamous cell carcinoma | Care and treatment | Research | Drug therapy | Cancer
Journal Article